Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O75531

UPID:
BAF_HUMAN

ALTERNATIVE NAMES:
Breakpoint cluster region protein 1

ALTERNATIVE UPACC:
O75531; O60558; Q6FGG7

BACKGROUND:
The Barrier-to-autointegration factor, alternatively known as Breakpoint cluster region protein 1, is essential for DNA integrity, chromatin structure maintenance, and cellular defense mechanisms. It prevents autointegration of retroviral DNA by retroviruses, including HIV, showcasing its significance in viral infection defense. The protein's ability to bridge distant DNA sites during anaphase underlines its critical role in maintaining genomic stability and ensuring proper cell division.

THERAPEUTIC SIGNIFICANCE:
Exploring the Barrier-to-autointegration factor's functions and its association with diseases like Nestor-Guillermo progeria syndrome offers a promising avenue for developing novel therapeutic approaches. Its role in mitigating DNA damage and regulating immune responses against foreign DNA presents valuable insights into potential drug targets for treating related genetic and autoimmune disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.